Big In Japan: Assessing Seven Years Of Sakigake
11 Global-First Approvals
Executive Summary
Japan’s fast-track approval system for innovative drug candidates has marked its seventh year since launch, during which it has accepted 27 candidates with 13 of these moving to approval. But in recent years the system has faced a decreasing number of admitted candidates, this original infographic analysis shows.
You may also be interested in...
Rocky Road To Glioma Approval: BNCT Firm Stella Redesigns Japan PII Trial
Japanese bioventure Stella Pharma is re-designing a Phase II trial for its glioma candidate Steboronine after it was determined the original primary endpoint was not robust enough to prove efficacy, a challenge faced by some others working in the difficult indication. The drug was approved for head and neck cancer in Japan in 2020 and Stella has already announced a new collaboration which may be key to moving forward.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.